* Janet Yellen to testify at 10 ET
* Fed to release Beige Book at 2 p.m. ET
* Futures up: Dow 27 pts, S&P 3.25 pts, Nasdaq 13.5 pts (Adds details, quote)
By Sweta Singh
July 12 (Reuters) - Wall Street looked set to open higher on Wednesday ahead of Federal Reserve Chair Janet Yellen's semi-annual monetary policy testimony before Congress.
The Fed Chair is expected to tell the House Financial Services Committee at 1000 ET that the central bank remains on a hawkish course of steadily rising rates.
Investors will be closely watching the testimony for any signals on how the bank is viewing a retreat in inflation and muted wage growth.
The U.S. central bank will also issue its Beige Book at 2 p.m. ET (1800 GMT), a compendium of anecdotes on the health of the economy. This will likely provide further evidence on the strength of the economy and give the Fed impetus to raise interest rates.
The Fed's next policy meeting is on July 25-26.
"We look for the markets to be choppy as the latest political saga overhangs and the forecast of the economic outlook remains favorable despite of a tighter monetary policy ahead," said Peter Cardillo, chief market economist at First Standard Financial.
U.S. stocks closed flat on Tuesday after clawing back from a fall as emails suggested Trump Jr. welcomed Russian help against Clinton in the 2016 presidential campaign. dollar on Wednesday failed to recover from the damage suffered from Trump's alleged links with Russia and held close to its lowest in more than a year against the euro.
Investors will also be keeping an eye on second-quarter earnings reports on Friday from big U.S. banks including JPMorgan Chase (NYSE: JPM ) JPM.N , Wells Fargo (NYSE: WFC ) WFC.N and Citigroup (NYSE: C ) C.N .
Dow e-minis 1YMc1 were up 27 points, or 0.13 percent, with 15,605 contracts changing hands.
U.S-listed shares of Ceragon Networks CRNT.O were up 4.7 pct at $2.65 premarket after the company received orders from a service provider in India. Therapeutix OCUL.O shares were down 32.2 pct at $5.15 after U.S. FDA rejected the company's post operative eye pain drug.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.